Editas Medicine Inc
EDIT2.330USD
-0.010-0.43%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
217.31MMarket Cap
LossP/E TTM
More Details of Editas Medicine Inc Company
Editas Medicine, Inc. is a genome-editing company developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology that includes CRISPR/Cas9, CRISPR/Cas12a, engineered forms and foundational intellectual property for both CRISPR systems. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide RNA molecule designed to recognize a particular DNA sequence. It is engaged in discovering, developing, manufacturing, and commercializing durable, precision in vivo gene-editing medicines for a broad class of diseases. Vivo medicines include vivo editing of hematopoietic stem cells (HSCs), liver cells and other tissues. Vivo gene editing in HSCs supports the advancement of research programs to treat non-malignant hematological diseases.
Editas Medicine Inc Info
Ticker SymbolEDIT
Company nameEditas Medicine Inc
IPO dateFeb 03, 2016
CEOO'Neill (Gilmore Neil)
Number of employees246
Security typeOrdinary Share
Fiscal year-endFeb 03
Address11 Hurley St
CityCAMBRIDGE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02141-2110
Phone16174019000
Websitehttps://www.editasmedicine.com/
Ticker SymbolEDIT
IPO dateFeb 03, 2016
CEOO'Neill (Gilmore Neil)
Company Executives of Editas Medicine Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Jessica Hopfield, Ph.D.
Dr. Jessica Hopfield, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
67.70K
--
Ms. Amy Parison
Ms. Amy Parison
Chief Financial Officer, Senior Vice President, Treasurer
Chief Financial Officer, Senior Vice President, Treasurer
15.91K
-2.82%
Dr. Gilmore O'Neill
Dr. Gilmore O'Neill
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. David T. Scadden, M.D.
Dr. David T. Scadden, M.D.
Independent Director
Independent Director
--
--
Dr. Linda C. Burkly, Ph.D.
Dr. Linda C. Burkly, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
--
--
Ms. Bernadette M. Connaughton
Ms. Bernadette M. Connaughton
Independent Director
Independent Director
--
--
Mr. Andrew J. Hirsch
Mr. Andrew J. Hirsch
Independent Director
Independent Director
--
--
Dr. Elliott M. Levy, M.D.
Dr. Elliott M. Levy, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Jessica Hopfield, Ph.D.
Dr. Jessica Hopfield, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
67.70K
--
Ms. Amy Parison
Ms. Amy Parison
Chief Financial Officer, Senior Vice President, Treasurer
Chief Financial Officer, Senior Vice President, Treasurer
15.91K
-2.82%
Dr. Gilmore O'Neill
Dr. Gilmore O'Neill
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. David T. Scadden, M.D.
Dr. David T. Scadden, M.D.
Independent Director
Independent Director
--
--
Dr. Linda C. Burkly, Ph.D.
Dr. Linda C. Burkly, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
--
--
Ms. Bernadette M. Connaughton
Ms. Bernadette M. Connaughton
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Nov 18
Updated: Tue, Nov 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
7.14%
BlackRock Institutional Trust Company, N.A.
6.98%
Two Sigma Investments, LP
2.86%
Geode Capital Management, L.L.C.
2.09%
Nuveen LLC
2.03%
Other
78.91%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
7.14%
BlackRock Institutional Trust Company, N.A.
6.98%
Two Sigma Investments, LP
2.86%
Geode Capital Management, L.L.C.
2.09%
Nuveen LLC
2.03%
Other
78.91%
Shareholder Types
Shareholders
Proportion
Investment Advisor
25.38%
Investment Advisor/Hedge Fund
12.13%
Hedge Fund
5.74%
Research Firm
3.44%
Individual Investor
0.27%
Venture Capital
0.27%
Bank and Trust
0.21%
Family Office
0.15%
Pension Fund
0.09%
Other
52.31%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
484
46.01M
66.91%
+6.07K
2025Q3
514
46.01M
73.15%
+1.44M
2025Q2
531
44.28M
80.90%
-3.80M
2025Q1
552
47.72M
85.69%
-24.01M
2024Q4
570
53.83M
81.01%
-4.72M
2024Q3
578
59.39M
82.29%
-828.60K
2024Q2
577
60.61M
96.25%
-11.62M
2024Q1
575
72.13M
87.72%
+356.11K
2023Q4
593
63.00M
93.99%
-2.58M
2023Q3
630
65.71M
94.67%
-1.93M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
7.16M
7.96%
-306.76K
-4.11%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
6.18M
6.87%
+97.51K
+1.60%
Jun 30, 2025
Two Sigma Investments, LP
1.92M
2.14%
-542.85K
-22.02%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.96M
2.18%
+20.52K
+1.06%
Jun 30, 2025
Nuveen LLC
934.16K
1.04%
+707.26K
+311.70%
Jun 30, 2025
State Street Investment Management (US)
1.85M
2.05%
+901.00
+0.05%
Jun 30, 2025
Renaissance Technologies LLC
888.40K
0.99%
-144.56K
-14.00%
Jun 30, 2025
UBS Asset Management Switzerland AG
1.17M
1.3%
+1.17M
--
Jan 31, 2025
SELECTRA Management Company S.A.
1.10M
1.23%
--
--
Jul 31, 2025
BofA Global Research (US)
1.08M
1.2%
-437.96K
-28.86%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
WisdomTree BioRevolution Fund
1.25%
Invesco NASDAQ Future Gen 200 ETF
0.64%
AXS Green Alpha ETF
0.46%
iShares Micro-Cap ETF
0.05%
Invesco Nasdaq Biotechnology ETF
0.03%
Vanguard US Momentum Factor ETF
0.03%
ProShares Ultra Nasdaq Biotechnology
0.03%
iShares Biotechnology ETF
0.02%
iShares Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
View more
WisdomTree BioRevolution Fund
Proportion1.25%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.64%
AXS Green Alpha ETF
Proportion0.46%
iShares Micro-Cap ETF
Proportion0.05%
Invesco Nasdaq Biotechnology ETF
Proportion0.03%
Vanguard US Momentum Factor ETF
Proportion0.03%
ProShares Ultra Nasdaq Biotechnology
Proportion0.03%
iShares Biotechnology ETF
Proportion0.02%
iShares Russell 2000 ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Editas Medicine Inc?
The top five shareholders of Editas Medicine Inc are:
The Vanguard Group, Inc. holds 7.16M shares, accounting for 7.96% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 6.18M shares, accounting for 6.87% of the total shares.
Two Sigma Investments, LP holds 1.92M shares, accounting for 2.14% of the total shares.
Geode Capital Management, L.L.C. holds 1.96M shares, accounting for 2.18% of the total shares.
Nuveen LLC holds 934.16K shares, accounting for 1.04% of the total shares.
The Vanguard Group, Inc. holds 7.16M shares, accounting for 7.96% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 6.18M shares, accounting for 6.87% of the total shares.
Two Sigma Investments, LP holds 1.92M shares, accounting for 2.14% of the total shares.
Geode Capital Management, L.L.C. holds 1.96M shares, accounting for 2.18% of the total shares.
Nuveen LLC holds 934.16K shares, accounting for 1.04% of the total shares.
What are the top three shareholder types of Editas Medicine Inc?
The top three shareholder types of Editas Medicine Inc are:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
Two Sigma Investments, LP
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
Two Sigma Investments, LP
How many institutions hold shares of Editas Medicine Inc (EDIT)?
As of 2025Q4, 484 institutions hold shares of Editas Medicine Inc, with a combined market value of approximately 46.01M, accounting for 66.91% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -6.23%.
What is the biggest source of revenue for Editas Medicine Inc?
In --, the -- business generated the highest revenue for Editas Medicine Inc, amounting to -- and accounting for --% of total revenue.
